Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Pharmaceuticals reported a strong financial performance for the second quarter of 2026, with a 17% year-over-year revenue growth on an adjusted basis. The CEO highlighted the successful commercial execution of both DAYBUE and NUPLAZID, attributing the growth to increased patient demand and uptake of STIX. This positive trend indicates a robust market position for Acadia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue growth of 17% year-over-year.
  • Strong commercial execution for DAYBUE and NUPLAZID.
  • Continued patient demand for DAYBUE.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
ACP-044 Dose A
Phase 2 · Acute Postoperative Pain

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q

Frequently Asked Questions

What were Acadia's Q2 2026 financial results?

Acadia reported a 17% year-over-year revenue growth for Q2 2026.

What products contributed to Acadia's revenue growth?

DAYBUE and NUPLAZID were key contributors to the revenue growth.

Who is the CEO of Acadia Pharmaceuticals?

Catherine Owen Adams is the CEO of Acadia Pharmaceuticals.

What drove the demand for DAYBUE?

Continued patient demand and robust uptake of STIX drove DAYBUE's demand.

ShareAdd on Google
Tags: ACAD Viatris Investor Conferences Healthcare Acadia Pharmaceuticals DAYBUE NUPLAZID financial results revenue growth
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$851M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ACP-044 Dose APhase 2
Acute Postoperative Pain →

Catalyst track record

+12%
best trade around ACAD's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ACAD.

See every catalyst's timing & PoA →